The Basel-based pharmaceutical company Roche has entered a cooperation agreement with the consultancy firm Accenture. The aim is to develop a data platform that connects diabetic patients, caregivers and healthcare providers.
The cooperation agreement between Roche and Accenture has a duration of five years, announced a statement. The platform developed within the agreement will unite products, solutions and services used in diabetes care.
Roche intends to use the new platform to improve personalised care for diabetics. “This collaboration agreement with Accenture is an exciting step forward to offering truly integrated diabetes management solutions,” commented Marcel Gmünder, Global Head of Roche Diabetes Care, in the statement.
Accenture will create Roche a platform that builds on the consultancy firm’s Intelligent Patient Platform. The platform will facilitate analytic evaluations that allow Roche to gain an insight into the demand for diabetes products and services in the future.
“The open diabetes platform we are creating will enable us to analyze large amounts of data through algorithms and put them into context, respond faster to the needs of people with diabetes, caregivers and healthcare systems and personalize treatment which all-in-all can lead to improved outcomes,” added Gmünder.
The development is another stage in Roche’s expansion of its diabetes activities. In June, the Basel-based pharma giant acquired mySugr GmbH, whose mobile diabetes platform allows diabetic patients to upload data from their measuring device into the mySugr diabetes diary app. Roche announced that the mySugr solution would be a key component of the new platform.
